MAPLE GROVE, Minn., Oct. 11, 2017 /PRNewswire/ -- Upsher-Smith Laboratories, LLC. (Upsher-Smith) today announced the launch of Exemestane Tablets, 25 mg. The company recently received U.S. Food and ...

BOCA RATON, Fla., Feb. 27, 2019 /PRNewswire/ -- Breckenridge Pharmaceutical, Inc. announced today that the U.S. Food and Drug Administration has granted final approval for its Abbreviated New Drug ...

San Antonio, December 8 – Pfizer announced today that it has submitted a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval for AROMASIN ...

Pfizer announced new, longer-term data from the Intergroup Exemestane Study (IES) showing that women who switched to Aromasin (exemestane tablets) after taking tamoxifen for 2-3 years experienced a ...

Sept. 19, 2005 — The European Commission has approved exemestane tablets for the treatment of estrogen receptor–positive invasive early breast cancer after two to three years of initial adjuvant ...

Pfizer Inc today announced new, longer-term data from the Intergroup Exemestane Study (IES) showing that women who switched to AROMASIN® (exemestane tablets) after taking tamoxifen for two to three ...

New York, Post-menopausal breast cancer patients who switched from tamoxifen to AROMASIN(R) (exemestane tablets) had a significantly reduced chance of recurrence and increased disease-free survival ...

Treatment of metastatic breast carcinoma is still controversial. The introduction of new cytotoxic drugs and new chemotherapic regimens has, up to now, not resulted in a significant increase in ...

PEAPACK, N.J. — Greenstone has introduced an authorized generic treatment for breast cancer, the generics subsidiary of Pfizer said. The company announced the launch of exemestane tablets, an ...